Nektar Therapeutics (NKTR) Cash from Operations Growth (3y) (2013 - 2026)
Nektar Therapeutics (NKTR) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Nektar Therapeutics | 1.80 Bn | 1.23 Bn | 3.16 Mn | 5.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.15% |
| Dec 31, 2025 | -4.03% |
| Sep 30, 2025 | 16.21% |
| Jun 30, 2025 | 15.20% |
| Mar 31, 2025 | 17.83% |
| Dec 31, 2024 | 32.70% |
| Sep 30, 2024 | 24.27% |
| Jun 30, 2024 | 23.10% |
| Mar 31, 2024 | 14.67% |
| Dec 31, 2023 | 21.87% |
| Sep 30, 2023 | 7.18% |
| Jun 30, 2023 | 15.00% |
| Mar 31, 2023 | 12.72% |
| Dec 31, 2022 | 22.76% |
| Sep 30, 2022 | -6.49% |
| Jun 30, 2022 | -11.62% |
| Mar 31, 2022 | -3.01% |
| Dec 31, 2021 | -8.83% |
| Sep 30, 2021 | -12.30% |
| Jun 30, 2021 | -27.78% |